Heterocyclic Compounds

Matches 551 - 600 out of 30,873	< 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 >

Document	Document Title
WO/2023/051495A1	ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS, AND COMPOSITION AND USE THEREOF The present invention relates to isoquinolinone and quinazolinone compounds as represented by formula (I) or (II), a pharmaceutical composition containing the compounds, and the use of the compounds and the pharmaceutical composition the...
WO/2023/053009A1	PYRIDINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES The present invention relates to pyridines and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
WO/2023/055178A1	NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME The present invention provides: a novel piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for the prevention or treatment of diseases rel...
WO/2023/049518A1	BENZIMIDAZOLE CARBOXYLIC ACIDS AS GLP-1R AGONISTS The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, o...
WO/2023/048118A1	COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT A purpose of the present invention is to provide a compound which is suitable for use as a material for the capping layer of an organic EL element, has a high refractive index in the wavelength range of 450-750 nm, and has a low extincti...
WO/2023/046133A1	DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are a dihydropyrimidine compound, a preparation method therefor and an application thereof, belonging to the technical field of pharmaceutical chemistry. The present invention relates to a dihydropyrimidine compound, the struct...
WO/2023/049691A1	CDK7 INHIBITORS AND METHODS OF TREATING CANCER Compounds of Formula (I) and pharmaceutically active salts thereof are provided, where the variables in Formula (I) are described herein. Such compounds and salts are CDK7 inhibitors that are useful for treating conditions characterized ...
WO/2023/046055A1	SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING α-KETONE FRAMEWORK, AND USE THEREOF Disclosed in the present invention are a substituted heterocyclic compound containing an α-ketone framework, and the use thereof, which relate to the field of medicinal chemistry. Specifically disclosed are a substituted heterocyclic co...
WO/2023/049888A1	BENZIMIDAZOLES AS MODULATORS OF IL-17 The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed her...
WO/2022/170974A9	TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS Provided are a compound of formula (I) that inhibit the activity of PARP7, a stereoisomer thereof, a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, an intermediate to prepare the compound, a process to prep...
WO/2023/049199A1	AZOLE COMPOUNDS Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including autoimmune diseases, inflammatory conditions a...
WO/2023/042483A1	COMPOUND, TAUTOMER THEREOF, SALT THEREOF WITH ALKALI METAL OR ORGANIC BASE, COMPOSITION FOR REVERSIBLE COLOR DEVELOPMENT, DYED MATERIAL, COMPOSITION FOR CULTURE MEDIUM FOR DETECTING ENTEROHEMORRHAGIC ESCHERICHIA COLI, AND METHOD FOR DETECTING ENTEROHEMORRHAGIC ESCHERICHIA COLI IN SPECIMEN A composition for a culture medium for detecting enterohemorrhagic Escherichia coli, said composition containing a compound represented by formula (1) or a compound represented by formula (2) and water. [In formulae (1) and (2): Ar1 and ...
WO/2023/043040A1	NOVEL COMPOUND FOR LIGHT-EMITTING DEVICE, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
WO/2023/042879A1	BICYCLIC HETEROCYCLIC DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...
WO/2023/042914A1	PYRROLIDINE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS Pyrrolidine compounds having an HDAC inhibition activity which are useful for treatment or prevention of diseases involving HDACs are provided. A compound of Formula [I], or a salt thereof, wherein R1 is an optionally substituted 6- to 1...
WO/2023/043923A1	CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
WO/2023/039662A1	PHENANTHRIDINIUM DERIVATIVES AS PPM1A INHIBITORS AND USES THEREOF The present disclosure provides compounds according to Formulas I and II: where R1 to R11 independently denote: H; D; a halogen; an optionally substituted straight chain or branched alkyl group; an optionally substituted alkenyl group; a...
WO/2023/044171A1	INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are prov...
WO/2023/043833A1	HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological...
WO/2023/043816A1	ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2023/043432A1	MITOCHONDRIAL THERAPEUTIC AGENTS The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 has any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds...
WO/2023/041905A1	AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE The present invention relates to PI3Kα activating compounds and pharmaceutical compositions comprising the same. The present invention further relates, inter alia, to the treatment of disorders susceptible to treatment by PI3Kα activat...
WO/2023/041432A1	3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT The invention relates to (3)-phenoxyazetidin-(1)-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention ...
WO/2023/043823A1	PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological...
WO/2023/043753A1	2-ARYL OR HETEROARYL-3-OXO-4-CARBAMIDE-6-CYCLIC-DIHYDROPYRAZINE ARYL HYDROCARBON RECEPTOR MODULATORS AND THEIR USE IN THE TREATMENT OF DISEASES AND DISORDERS Disclosed herein are compounds which can act modulators of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating diseases and disorders, such as cancer and viral infections, using the compounds disclosed ...
WO/2023/043284A1	FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS The invention provides novel substituted heterocyclic rings represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compou...
WO/2023/038815A1	IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS Disclosed herein is method for treating and/or preventing a cytokine release-related condition associated with infection by a respiratory virus, e.g., COVID-19 or influenza. In certain embodiments, the method may comprise administering a...
WO/2023/039603A2	BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific pro...
WO/2023/039275A1	AHR AGONISTS The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.
WO/2023/039170A1	SELECTIVE TARGETING OF CD38 ACTIVITY AS AN IMMUNOSTIMULATORY AND ANTITUMOR STRATEGY The present invention relates compounds having the general structure of formulas I and II, and other compounds having similar activity, including any pharmaceutically acceptable salts thereof. The invention includes the use of such compo...
WO/2023/039010A1	COMPOUNDS AND THEIR USES FOR TREATING NEURODEGENERATIVE DISEASE Disclosed herein are compounds designed and used in the degradation of pathogenic protein aggregates and oligomers, thus these compounds are suitable for use as medicaments for preventing and/or treating neurodegenerative diseases such a...
WO/2023/039601A1	BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific pro...
WO/2023/039604A1	BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific pro...
WO/2023/036934A1	CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYLPYRIDINE DERIVATIVES The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulphonyl-pyridine derivatives of formula (I),wherein the variables are as defined in the description and in the claims, which can be used as antiparasitic agents...
WO/2023/039602A1	BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific pro...
WO/2023/039278A1	AHR AGONISTS The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.
WO/2023/030295A1	UBIQUITIN SPECIFIC PROTEASE 1 (USP1) INHIBITOR A compound having a USP1 inhibitory activity or function and a pharmaceutically acceptable salt thereof. The compound has the structure of formula (I), and have substituents and structural features described in the present invention. Als...
WO/2023/034836A1	COMPOUNDS AND METHODS FOR MODULATING SPLICING The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
WO/2023/031440A1	2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM The present invention relates to a compound that binds to and modulates the activity of sortilin, wherein the compound has a blood-to-brain Kpuu greater than 0.1. The compounds are capable of crossing the blood brain barrier and are suit...
WO/2023/034946A1	INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS The invention relates to heterocyclic compounds of formulae (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods...
WO/2023/034827A1	COMPOUNDS AND METHODS FOR MODULATING SPLICING The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
WO/2023/034411A1	COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL Compounds, compositions, and methods for controlling the level of a target protein in a cell are described. Compounds of the disclosure include those having according to the formula PTM-L-LTM, wherein PTM is a targeting moiety that binds...
WO/2023/034992A1	INDOLE COMPOUNDS AND METHODS OF USE The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and...
WO/2023/028054A1	QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE Described herein are inhibitors of EGFR exon 20 insertion mutants and methods of treating cancer comprising the administration of said inhibitors.
WO/2023/023853A1	TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS FOR USE AS THERAPEUTICS This invention provides compound having a structure of Formula (I)or (II): (I, II ) and uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are a...
WO/2023/028056A1	3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Z1, Z2, R3 - R8, RA, ring A, and n have the meanings described herein, and compositions containing such compounds and methods for usin...
WO/2023/025861A1	NEW VASHS INHIBITORS, CONJUGATES THEREOF AND THEIR USES AS DRUGS OR AS RESEARCH TOOLS The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools.
WO/2023/028534A1	INHIBITORS OF NLRP3 The present invention relates to novel compounds of Formulae I-XI: wherein each A, A', Q, Q', W, Rw, Y, and Z, and -- are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further r...
WO/2023/028235A1	EIF4E INHIBITORS AND USES THEREOF The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.
WO/2023/025136A1	ISOINDOLINONE COMPOUND AND USE THEREOF Provided are an isoindolinone compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, and a use thereof in the treatment of proliferative diseases. Further provided is a pharmaceutical composition co...

Matches 551 - 600 out of 30,873	< 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 >